Opioid effectiveness and side effects in chronic pain

Anesthesiology Clinics of North America

Volumn 21, Issue 4, 2003, Pages 699-713

  Christo, Paul J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; AMANTADINE; ANTIHISTAMINIC AGENT; BENZODIAZEPINE DERIVATIVE; CALAMINE; CALCIUM CHANNEL BLOCKING AGENT; CISAPRIDE; CLONAZEPAM; CLONIDINE; DEXTROMETHORPHAN; DIAZEPAM; HALOPERIDOL; KETAMINE; LAXATIVE; METHADONE; METOCLOPRAMIDE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALMEFENE; NALOXONE; NIMODIPINE; OPIATE; OPIATE ANTAGONIST; PENTAZOCINE; TESTOSTERONE;

ANALGESIA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DELIRIUM; DEPERSONALIZATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; DYSPHORIA; HUMAN; HYPNOSIS; HYPOGONADISM; HYPOPROTEINEMIA; ILLUSION; KIDNEY DISEASE; LIVER DYSFUNCTION; MYOCLONUS; NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PATIENT CARE; PRURITUS; RESPIRATION DEPRESSION; REVIEW; SEDATION; SIDE EFFECT; SKIN STIMULATION; STOMACH MOTILITY; UNPLEASANT DREAM; URINALYSIS; VOMITING;

EID: 0347993728     PISSN: 08898537     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8537(03)00087-7     Document Type: Review

References (60)

1. Brookoff D. Chronic pain: A new disease? Hosp Pract 2000;7:1-18.
2. Gutstein HB. Opioid analgesics. In: Hardman JG, Limbird LL, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 10th edition. New York: McGraw-Hill; 2001. p. 569-619.
3. Foley KM. Problems of overarching importance, which transcend organ systems. In: Bennett JC, Plum F, editors. Cecil Textbook of medicine. Philadelphia: Saunders; 1996. p. 100-7.
4. American Pain Society. Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain. 4th edition. Glenview, IL: American Pain Society; 1999.
5. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990;43:273-86.
6. Bruera E, MacMillan K, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: preliminary report. Pain 1989;37:203-10.
7. Portenoy RK. Opioid tolerance and responsiveness: research findings and clinical observations. Proceedings of the 7th World Congress on Pain, Progress in Pain Research and Management 1994; 2:595-614.
8. Hanks GW. The pharmacological treatment of bone pain. Cancer Surv 1988;7:87-100.
9. Kupers RC, Konings H, Adriaensen H, Gybels JM. Morphine differntially affects the sensory and affective pain ratings in neurogenic and ideopathic forms of pain. Pain 1991;47(1):5-12.
10. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988;33:11-23.
11. Mercadante S, Maddaloni S, Roccella S, Salvaggio L. Predictive factors in advanced cancer pain treated only by opioids. Pain 1992;50(2):151-5.
12. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: Report of five cases. Pain 1992;49:87-91.
13. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998;50:1837-41.
14. Rowbotham MC, Lisa Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral Opioid Therapy for Chronic Peripheral and Central Neuropathic Pain. N Engl J Med 2003;348:1223-32.
15. Raja SN, Haythornthwaite JA, Pappagallo M, Clark MR, Travison TG, Sabeen S, et al. Opioids versus antidepressants in postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
16. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: a combined analysis of controlled, single-dose studies. Neurology 1994;44:857-61.
17. McQuay HJ, Jadad AR, Carroll D, Faura C, Glynn CJ, Moore RA, et al. Opioid sensitivity of chronic pain: a patient-controlled analgesia method. Anaesthesia 1992;47:757-67.
18. Jadad AR, Carroll D, Glynn CJ, Moore RA, McQuay HJ. Morphine responsiveness of chronic pain: double-blind randomised crossover study with patient-controlled analgesia. Lancet 1992; 339(8806):1367-71.
19. Benedetti F, Vighetti S, Amanzio M, Casadio C, Oliaro A, Bergamasco B, et al. Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain. Pain 1998;74:205-11.
20. Thomas Z, Bruera E. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manage 1995;10:315-7.
21. Sengupta JN, Su X, Gebhart GF. Kappa, but not mu or delta, opioids attenuate responses to distention of afferent fibers innervating the rat colon. Gastroenterology 1996;111:968-80.
22. Ghorpade A, Advokat C. Evidence of a role for NMDA receptors in the facilitation of tail withdrawal after spinal transection. Pharmacol Biochem Behav 1994;48:175-81.
23. Persson J, Axelsson G, Hallin RG, Gustafsson LL. Beneficial effects of ketamine in a chronic pain state with allodynia, possibly due to central sensitization. Pain 1995;60:217-22.
24. Mercadante S, Arcuri E, Tirelli W, Casuccio A. Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J Pain Symptom Manage 2000;20:246-52.
25. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manage 2001;21:338-49.
26. Santillan R, Maestre JM, Hurle MA, Florez J. Enhancement of opiate analgesia by nimodipine in cancer patients chronically treated with morphine: a preliminary report. Pain 1994;58:129-32.
27. Roca G, Aguilar JL, Gomar C, Mazo V, Costa J, Vidal F. Nimodipine fails to enhance the analgesic effect of slow release morphine in the early phases of cancer pain treatment. Pain 1996;68:239-43.
28. Puke MJ, Wiesenfeld-Hallin Z. The differential effects of morphine and the alpha 2 adrenoreceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pain. Anesth Analg 1993;77:104-9.
29. Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain 1995;61:391-9.
30. Stevens C, Yaksh T. Opioid and adrenergic spinal receptor systems and pain control. NIDA Res Monogr 1988;81:343-52.
31. Xu XJ, Puke MJ, Wiesenfeld-Hallin Z. The depressive effect of intrathecal clonidine on the spinal flexor reflex is enhanced after sciatic nerve section in rats. Pain 1992;51:145-52.
32. Mercadante S, Casuccio A, Fulfaro F, Groff L, Boffi R, Villari P, et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 2001;19:2898-904.
33. Mao J, Price DD, Caruso FS, Mayer DJ. Oral administration of dextromethorphan prevents the development of morphine tolerance in rats. Pain 1996;67:361-8.
34. Bem JL, Peck R. Dextromethorphan: an overview of safety issues. Drug Saf 1992;7:190-9.
35. Gottschalk A, Schroeder F, Ufer M, Oncu A, Buerkle H, Standl T. Amantadine, a n-methyl-d-aspartate receptor antagonist, does not enhance postoperative analgesia in women undergoing abdominal hysterectomy. Anesth Analg 2001;93:192-6.
36. Heiskanen T, Hartel B, Dahl ML, Seppala T, Kalso E. Analgesic effects of dextromethorphan and morphine in patients with chronic pain. Pain 2002;96:261-7.
37. Levine JD, Gordon NC, Taiwo YO, Coderre TJ. Potentiation of pentazocine analgesia by low-dose naloxone. J Clin Invest 1988;82:1574-7.
38. Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 1997;87: 1075-81.
39. Joshi GP, Duffy L, Chehade J, Wesevich J, Gajraj N, Johnson ER. Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia. Anesthesiology 1999;90:1007-11.
40. Bruera E, MacMillan K, Hanson J, MacDonald RN. The Edmonton staging system for cancer pain: Preliminary report. Pain 1989;37:203-10.
41. Haythornthwaite JA, Menefee LA, Quatrano-Piacentini AL, Pappagallo M. Outcome of chronic opioid therapy for non-cancer pain. J Pain Symptom Manage 1998;15:185-94.
42. Tassain V, Attal N, Fletcher D, Brasseur L, Degieux P, Chauvin M, et al. Long term effects of oral sustained release morphine on neuropsychological performance on patients with chronic non-cancer pain. Pain 2003;104:389-400.
43. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long term morphine analgesia. Lancet 1995;346:667-70.
44. Sjogren P, Thunedborg LP, Christrup L, Hansen SH, Franks J. Is development of hyperalgesia, allodynia and myoclonus related to morphine metabolism during long-term administrations? Acta Anaesthesiol Scand 1998;42:1070-5.
45. Morley JS, Miles JB, Wells JC, Bowsher D. Paradoxical pain. Lancet 1992;340:1045.
46. Gong QL, Hedner J, Bjorkman R, Hedner T. Morphine 3 glucuronide may functionally antagonize morphine 6 glucuronide induced antinociception and ventilatory depression in the rat. Pain 1992; 48:249-55.
47. Mercadante S. Opioids and akathisia. J Pain Symptom Manage 1995;10(6):415.
48. Kreek MJ. Physiologic implications of methadone treatment. Proc Natl Conf Methadone Treat 1973;2:824-38.
49. Kreek MJ. Medical complications in methadone patients. Ann N Y Acad Sci 1978;311:110-34.
50. De Leon G, Wexler HK. Heroin addiction: its relation to sexual behavior and sexual experience. J Abnorm Psychol 1973;81:36-8.
51. Pelosi MA, Sama JC, Caterini H, et al. Galactorrhea-amenorrhea syndrome associated with heroin addiction. Am J Obstet Gynecol 1974;118:966-70.
52. Wang C, Chan V, Yeung RTT. The effect of heroin addiction on pituitary-testicular function. Clin Endocrinol 1978;9:455-61.
53. Cicero TJ, Bell RD, Wiest WG, Allison JH, Polakoski K, Robins E. Function of the male sex organs in heroin and methadone users. N Engl J Med 1975;292:882-7.
54. Paice JA, Penn RD, Ryan WG. Altered sexual function and decreased testosterone in patients receiving intraspinal opioids. J Pain Symptom Manage 1994;9:126-31.
55. Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg 1996;85:458-67.
56. Finch PM, Roberts LJ, Price L, et al. Hypogonadism in patients treated with intrathecal morphine. Clin J Pain 2000;16:251-4.
57. Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 2000;85: 2215-22.
58. Roberts LJ, Finch PM, Goucke CR, Prince LM. Outcome of intrathecal opioids in chronic non-cancer pain. Eur J Pain 2001;4:353-61.
59. Roberts LJ, Finch PM, Pullan PT, Bhagat CI, Price LM. Sex Hormone Suppression by Intrathecal Opioids: A Prospective Study. Clin J Pain 2002;18:144-8.
60. Jordan D, Tafani JAM, Ries C, et al. Evidence for multiple opioid receptors in the human posterior pituitary. J Neuroendocrinol 1996;8:883-7.